Fresenius Kabi, a division of Fresenius, has launched Tyenne® (tocilizumab-aazg) in the U.S., a biosimilar of Actemra® (tocilizumab), approved by the FDA on March 5, 2024. Tyenne® is available in both intravenous and subcutaneous formulations, marking a significant advancement in autoimmune disease treatment options. This launch is a part of Fresenius’ strategic focus on its (Bio)Pharma business, aiming to expand its portfolio and reach more patients. With Tyenne®, Fresenius Kabi aims to address the treatment needs of patients with autoimmune diseases, including rheumatoid arthritis and systemic juvenile idiopathic arthritis.
Pierluigi Antonelli, CEO of Fresenius Kabi, emphasizes the impact of Tyenne® on the U.S. healthcare landscape and the company’s commitment to providing comprehensive patient support. Tyenne® joins Fresenius Kabi’s existing biosimilars, Idacio® and Stimufend®, further strengthening its position in the autoimmune and oncology treatment markets. For more information on Tyenne® and Fresenius Kabi’s patient support program, click here.
Fresenius’ strategic direction, outlined in #FutureFresenius, focuses on becoming a leading therapy-focused company by streamlining its structure and enhancing performance. Tyenne®, developed using advanced technologies, offers an effective treatment option for autoimmune diseases, while also acknowledging potential risks associated with its use.
